Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 16/20 | 0.54 |
| ▸ | CNR2 | P34972 | 10/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804830 | 1.00 | FDFT1 (0.60) | FDFT1NPC1RAB9ACNR1CNR2 | |
| SCHEMBL13804814 | 0.95 | FDFT1 (0.62) | FDFT1NPC1RAB9ACNR1CNR2 | |
| SCHEMBL3525023 | 0.95 | FDFT1 (0.62) | FDFT1NPC1RAB9ACNR1CNR2 | |
| SCHEMBL3527929 | 0.81 | FDFT1 (0.73) | FDFT1CNR1CNR2 | |
| SCHEMBL13804833 | 0.81 | FDFT1 (0.73) | FDFT1CNR1CNR2 | |
| SCHEMBL6738171 | 0.81 | FDFT1 (0.66) | FDFT1CNR1CNR2 | |
| SCHEMBL13804850 | 0.80 | CNR1 (0.65) | FDFT1CNR1CNR2 | |
| SCHEMBL3527893 | 0.80 | CNR1 (0.65) | FDFT1CNR1CNR2 | |
| SCHEMBL5262269 | 0.78 | CNR1 (0.63) | FDFT1RAB9ACNR1CNR2 | |
| SCHEMBL14064682 | 0.78 | CNR1 (0.48) | FDFT1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234061-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | claimed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | claimed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| US-6972295-B2 | Substituted amides | MERCK & CO., INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050234061-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | FDFT1 2654/4885NPC1 337/4885RAB9A 1073/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | FDFT1 3461/4885NPC1 279/4885RAB9A 915/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | FDFT1 2654/4885NPC1 337/4885RAB9A 1073/4885 |
| US-20050234061-A1 | Substituted amides | CNR1, CNR2, FAAH | FDFT1 2654/4885NPC1 337/4885RAB9A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.